Candida Fungal Eye Infection: Symptoms, Risks, and Treatments

Candida fungal eye infections are uncommon but genuinely dangerous, capable of causing permanent vision loss if treatment is delayed even by days. The yeast, most often Candida albicans, can attack the cornea from the outside or seed into deeper structures like the retina and vitreous humor through the bloodstream. Because the symptoms often mimic bacterial infections or look deceptively mild at first, many cases are initially misdiagnosed or treated with the wrong drugs, which lets the fungus dig in further.

How Candida Infects the Eye

There are two fundamentally different routes. In the first, Candida lands on the surface of the cornea and causes keratitis, an infection of the clear front window of the eye. This is the exogenous route: the fungus arrives from outside, typically through a break in the corneal surface. In the second, Candida is already circulating in the bloodstream (a condition called candidemia) and seeds into the retina, choroid, or vitreous cavity. That internal infection is called endogenous endophthalmitis, and it tends to be far more destructive because the fungus is deep inside the eye where drugs have trouble reaching.

In one study of 42 Candida eye isolates, keratitis accounted for 29 cases and endophthalmitis for 12, with one case of orbital cellulitis.¹ These two forms of infection differ in who gets them, what the warning signs look like, and how aggressively they need to be treated.

Which Candida Species Are Involved

Candida albicans remains the most common culprit, but the landscape is shifting. Infections caused by non-albicans species such as C. tropicalis, C. parapsilosis, and C. glabrata have been rising in frequency.² This matters because different species respond differently to antifungal drugs, and some form biofilms more readily than others.

The species also differs depending on how the infection started. In endogenous infections, where Candida arrives via the bloodstream, C. albicans dominates overwhelmingly, accounting for over 90% of cases in one series. In exogenous infections that enter through the cornea, non-albicans species made up the majority, with C. tropicalis and C. parapsilosis each appearing in roughly a fifth of cases.³ Research in mice and humans confirms that C. albicans produces a more aggressive inflammatory response inside the eye and is significantly more likely to cause ocular complications when it spreads through the blood, compared with C. parapsilosis even when the latter is a more common bloodstream pathogen overall.⁴

Symptoms to Watch For

The warning signs depend on which part of the eye is infected, and the treacherous thing about Candida eye infections is that symptoms can start subtly or even be absent altogether.

With Candida keratitis, you typically notice eye pain, redness, tearing, light sensitivity, and blurred vision. The cornea develops a whitish infiltrate, sometimes with satellite lesions around the main spot, a pattern that hints at fungal rather than bacterial infection. The onset is often slower and more smoldering than a bacterial corneal ulcer, which can actually delay diagnosis since both the patient and the clinician may assume the infection is less serious than it is.

Endogenous Candida endophthalmitis can be especially insidious. Classic signs include floaters, blurred or hazy vision, and eye pain, but nearly half of patients with bloodstream-seeded eye involvement in one study had no eye complaints at all.⁵ That is a real problem: if you are already hospitalized and critically ill with a Candida bloodstream infection, a quiet eye infection can progress unchecked unless someone actively looks for it. On examination, the hallmark is yellow-white fluffy retinal lesions, sometimes described as “cotton ball” or “string of pearls” appearances, along with vitreous haze and possible hemorrhages.

Who Is at Risk

The risk factors differ sharply for corneal infections versus infections that arrive through the bloodstream.

Corneal (Exogenous) Risks

Candida keratitis tends to develop in eyes that are already compromised. In one case series, the most common risk factors were topical steroid use (present in about three-quarters of patients), pre-existing ocular surface disease (about 70%), contact lens wear (roughly half), and prior corneal surgery (about 40%). Every patient had at least two of these factors at once.⁶ Steroid eye drops are particularly risky because they suppress the local immune response on the corneal surface, giving the yeast a foothold. Contact lenses create a warm, moist microenvironment and can cause tiny abrasions that serve as entry points.

Bloodstream (Endogenous) Risks

Endogenous Candida endophthalmitis is essentially a complication of candidemia. Having a central venous catheter carried the highest risk in one logistic regression analysis, with an odds ratio above 8. Intravenous drug use, immunosuppression, and total parenteral nutrition all significantly increased risk as well, and C. albicans species in particular was more likely than other species to seed the eye.⁷ A separate large analysis confirmed that IV drug use, solid organ transplantation, diabetes with chronic complications, cirrhosis, Candida endocarditis, and even radiation therapy each independently increased the chance of the bloodstream infection spreading to the eye.⁸

How Candida Eye Infections Are Diagnosed

The cornerstone of diagnosis is a thorough eye exam. For endophthalmitis, indirect ophthalmoscopy remains the reference standard for visualizing the retina and looking for characteristic lesions.⁹ Optical coherence tomography (OCT) can add useful detail: Candida endophthalmitis tends to produce distinctive vitreous condensations sometimes called a “rain-cloud sign,” preretinal aggregates, and fluid within the retinal layers, a pattern that can help distinguish it from Aspergillus and other fungal infections.¹⁰

Laboratory confirmation is trickier than you might expect. Culturing vitreous or corneal samples is the traditional approach, but yields are limited, especially for deeper infections. PCR testing has emerged as a more sensitive alternative. In one early report, PCR detected C. albicans DNA in all four tested vitreous samples from suspected cases, including two where standard cultures came back negative.¹¹ Despite advances, many corneal ulcers worldwide are still treated based on clinical appearance alone without microbiological confirmation, which contributes to both poor outcomes and growing drug resistance.¹²

The Screening Debate for Hospitalized Patients

If you have Candida in your bloodstream, should an eye doctor automatically examine you? This question has generated real disagreement among infectious disease and ophthalmology specialists. The Infectious Diseases Society of America has historically recommended routine ophthalmologic exams for everyone with candidemia. The American Academy of Ophthalmology pushed back, arguing that routine screening of candidemia patients is low-value because endophthalmitis rates have dropped below 1% in recent systematic reviews and the eye exam findings rarely change the overall treatment plan.¹³

A systematic review in JAMA Ophthalmology found that among more than 7,400 screened candidemia patients, as few as 3 had a potential improvement in outcome from the eye exam, suggesting that blanket screening does not appear to be supported by the literature.¹⁴ A more recent study found that about 6% of examined candidemia patients had presumed Candida chorioretinitis, but none had definitive endophthalmitis, and the number needed to screen to catch one asymptomatic case was 20. Eye involvement was more likely to be found when the exam happened more than a week after the first positive blood culture.⁵

The practical upshot: if you develop visual symptoms while being treated for a Candida bloodstream infection, an urgent eye exam is clearly warranted. Whether every asymptomatic candidemia patient benefits from a routine eye check remains an open and actively debated question, with the risk-benefit calculation leaning against universal screening in recent analyses.

Treatment Options

Treatment depends on which part of the eye is involved and how deep the infection has penetrated. The options range from eye drops alone to systemic drugs and surgery, and many patients end up needing a combination.

Topical Antifungals for Corneal Infections

Candida keratitis is typically treated with frequent antifungal eye drops. Natamycin and amphotericin B drops are traditional workhorses. Voriconazole 1% eye drops have shown promise as a first-line option: in one case report, hourly application resolved both the corneal infiltrate and the epithelial defect within days, with vision improving from severely impaired to near-normal.¹⁵ Miconazole eye drops have also been studied and performed similarly to fluconazole drops in an animal model of Candida keratitis, with no visible eye toxicity.¹⁶ In severe corneal infections, systemic antifungal drugs are often added alongside the drops.¹⁷

Systemic and Intravitreal Therapy for Endophthalmitis

When Candida reaches the inside of the eye, topical drops alone cannot do the job. Systemic antifungals, most commonly fluconazole or voriconazole, are the backbone of treatment. These drugs are given intravenously or orally at high doses to achieve adequate concentrations inside the eye. Cure rates with systemic antifungals alone are considerably better when the infection is confined to the choroid and retina (chorioretinitis) than when it has spilled into the vitreous humor.¹⁸

When the infection involves the vitreous or is worsening despite systemic drugs, intravitreal injections of antifungals deliver medication directly where it is needed. Amphotericin B is the most established intravitreal agent. Intravitreal fluconazole has also been used, particularly in patients who cannot undergo surgery or tolerate full-dose systemic therapy, such as those with severe liver or kidney disease.¹⁹ A combination of systemic plus intravitreal antifungals, with possible surgery, is the standard approach for fungal endophthalmitis.²⁰

Surgical Interventions

Pars plana vitrectomy, a procedure that removes the infected vitreous gel from inside the eye, is recommended for moderate-to-severe vitritis and significant vision loss.¹⁸ By physically removing the mass of fungal organisms and inflammatory debris, vitrectomy can accomplish what drugs alone sometimes cannot. It is typically combined with intravitreal amphotericin B injected at the end of the procedure.²¹

For corneal infections that fail to respond to medication, therapeutic keratoplasty (a corneal transplant performed to clear infection rather than just to restore vision) is an option. In one large series, about 80% of patients with advanced suppurative keratitis achieved therapeutic success after a single transplant procedure, with similar one-year survival rates for bacterial and fungal infections.²²

Visual Outcomes and What Determines Them

The prognosis for Candida eye infections varies enormously depending on how deep the infection goes and how quickly treatment starts. Final visual acuity is strongly correlated with the stage of infection at the time of the initial examination.²³ Put simply, the earlier the infection is caught, the better the odds of preserving useful vision.

A multicenter retrospective study found that persistent vision loss of some degree occurred in about 20% of candidemia patients with ocular involvement, and all of those patients had been symptomatic from the start.²⁴ The depth of the lesion matters as well. In a longitudinal cohort study, patients whose infection extended into the choroidal and retinal layers had significantly worse vision at twelve months compared to those with shallower intraretinal or preretinal lesions. Nearly all of the deeper-infection eyes developed a secondary complication called macular neovascularization, while none of the shallower-infection eyes did.²⁵ Those secondary blood vessel growths can cause ongoing damage well after the infection itself has cleared.

Why Biofilms Make Treatment Harder

One reason Candida eye infections can be stubborn is the organism’s ability to form biofilms, organized communities of cells embedded in a protective matrix. A biofilm acts like a shield, making the fungi inside it far more resistant to antifungal drugs than free-floating cells. This is compounded by the already difficult problem of getting antifungal drugs to penetrate ocular tissues at adequate concentrations.² Biofilm formation is one reason that infections on contact lenses, intraocular lens implants, or other foreign surfaces in the eye can be particularly difficult to eradicate and sometimes require removal of the implant itself.

Candida Eye Infections in Newborns

Premature infants with systemic candidiasis are a unique and vulnerable group. Their eye infections develop through the bloodstream, just like adult endogenous endophthalmitis, but the clinical picture and treatment approach differ in important ways. Eye involvement in infants with systemic candidiasis now occurs in only about 6% of cases, down from earlier decades thanks to earlier systemic antifungal treatment. The characteristic finding is the same yellow-white fluffy retinal or vitreous lesion seen in adults, often with hemorrhage. C. albicans and C. tropicalis are the predominant species in newborns.²⁶

One unusual complication in neonates is lens abscess, where Candida seeds into the lens of the eye before the blood vessels that supply it during fetal development have fully regressed. Once those vessels disappear, the lens becomes avascular, creating a pocket where antifungal drugs cannot easily reach. Lensectomy, or surgical removal of the lens, is sometimes the only way to clear both the infection and the visual obstruction.²⁶

Despite the alarming sound of all this, the good news is that outcomes in premature infants tend to be better than in adults when treated promptly with systemic antifungals alone. A long-term follow-up study of 11 premature infants with Candida endophthalmitis found minimal residual eye damage when the infants were treated with systemic antifungals without vitrectomy or intravitreal injections, and the authors recommended against performing those invasive procedures in this population.²⁷

Endogenous Versus Exogenous Infections

The distinction between infections that arrive from inside the body and those that come from outside is not just academic. Beyond the difference in species distribution already mentioned, the two forms behave differently in terms of severity, treatment, and the patient profile. Endogenous infections arise in people who are typically already very sick: hospitalized, immunocompromised, or using intravenous drugs. The infection often affects the posterior segment (retina and vitreous) and requires systemic drugs with or without surgery. Exogenous infections, by contrast, tend to start at the cornea and are more common in people with local eye problems such as prior surgery, contact lens use, or chronic steroid drops. These infections are more likely to involve non-albicans species that may carry different drug sensitivities.³

This means the same organism, Candida, can cause eye infections in two very different patient populations, each requiring a different diagnostic mindset. In a hospitalized ICU patient with a central line and positive blood cultures, ophthalmologists are looking deep inside the eye for retinal lesions. In a contact lens wearer who shows up at the emergency room with a painful red eye, the focus is on the cornea. Recognizing which clinical scenario you are in shapes everything from the urgency of the workup to the choice of drugs.